Slide 1: Third Quarter 2023 Results Conference Call and Webcast
Third Quarter 2023 Results Conference Call and Webcast November 7, 2023 Nasdaq: ZYME | zymeworks.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary include “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchan
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures In addition to reporting financial information in accordance with generally accepted accounting principles (“GAAP”) in this presentation, Zymeworks is also reporting selected non-GAAP, or adjusted, financial measures, including adjusted research and development expenses a
Slide 4: Q3 Earnings Results Call Agenda
Q3 Earnings Results Call Agenda Chris Astle, PhD Paul Moore, PhD Ken Galbraith SVP & CFO CSO Chair and CEO • Financial Update • ZW251 • Q&A • Q&A • R&D Update • Q&A Making a Meaningful Difference 4
Slide 5: Chris Astle, Ph.D.
Chris Astle, Ph.D. Senior Vice President & Chief Financial Officer Making a Meaningful Difference 5
Slide 6: Q3 2023 Financial Results – Nine Months Ended
Q3 2023 Financial Results – Nine Months Ended Nine months ended Nine months ended • Revenue increased by $49.1 million which included In millions USD Sept 30, 2023 Sept 30, 2022 development support and drug supply revenue from Jazz, net of a credit issued to Jazz for amendments to our partnership Re
Slide 7: Paul Moore, Ph.D.
Paul Moore, Ph.D. Chief Scientific Officer Making a Meaningful Difference 7
Slide 8: Zanidatamab: Clinical Takeaways from ESMO
Zanidatamab: Clinical Takeaways from ESMO Phase 1b/2 study for zanidatamab plus chemo and Quality of life outcomes from the Phase 2b HERIZON-BTC- tislelizumab in GEA 01 study on health-related quality of life ("HRQoL") Updated Results Presented by BeiGene (ESMO 2023) Results Presented by Jazz (ESMO
Slide 9: 5x5 R&D Strategy: Diversified Portfolio Provides Multiple Opportunities for Success
5x5 R&D Strategy: Diversified Portfolio Provides Multiple Opportunities for Success ZW191 ZW171 Antibody Drug Conjugate Bispecific T-Cell Engager (2+1) targeting folate receptor alpha targeting pancreatic, mesothelioma, expressing tumors including ovarian, and other mesothelin- ZW171 ZW191 ovarian,
Slide 10: ZW251: A potential first-in-class GPC3-targeting topoisomerase I inhibitor ADC
ZW251 A potential first-in-class GPC3- targeting topoisomerase I inhibitor ADC Nasdaq: ZYME | zymeworks.com 10
Slide 11: HCC Epidemiology and Current Treatment
HCC Epidemiology and Current Treatment HCC Burden Standard of Care for Systemic HCC • Globally 6th most common cancer and third most common • In the US, most patients receive IO-VEGF or IO-IO combinations cause of death from cancer in 1L; multi-targeted TKIs are a 2L option 5-Year Relative Survival,
Slide 12: GPC3 is prevalent and highly expressed in hepatocellular carcinoma
GPC3 is prevalent and highly expressed in hepatocellular carcinoma Normal HCC #1 HCC #2 HCC % Positivity Intensity Reference 87% 57% IHC2+/3+ Abou-Alfa et al. 2016. J Hepatol 96% 75% ‘++’, 3% ‘+++’ Wang et al. 2016. Oncotarget 84% 84% ‘++’ Yamauchi et al. 2005. Mod Pathol Wang et al. 2008. Arch Path
Slide 13: ZW251: Glypican 3-targeting ADC
ZW251 Glypican 3-targeting ADC Design • An IgG1 antibody designed for potential optimization of ADC characteristics • Topoisomerase 1 inhibitor mechanism of action • Moderate potency payload with bystander activity (ZD06519) • Intermediate drug-to-antibody ratio ~ 4 • Validated peptide cleavable lin
Slide 14: ZW251: Potent Antitumor Activity and Favorable Safety Profile in Preclinical Models
ZW251: Potent Antitumor Activity and Favorable Safety Profile in Preclinical Models Differentiated Modality ZW251 Is Well-Tolerated In A Repeat Dose Non- Demonstrates Anti-Tumor Human Primate Toxicology Study Activity in HCC models Day 1 Day 22 Day 43 Day 50 HCC PDX GPC3 H-Score: 225 Necropsy Tumour
Slide 15: Integrated Platforms Help Drive Growing Product Candidate Pipeline
Integrated Platforms Help Drive Growing Product Candidate Pipeline Late- Research and Early-Development Portfolio Target IND-Enabling Phase 1 Phase 2 Phase 3 Anticipated Discovery Milestone Zanidatamab HER2 BTC, GEA, BC, and other solid tumors* Expected GEA pivotal data 2024 Zanidatamab Zovodotin (Z
Slide 16: On A Mission to Improve the Standard of Care For Difficult to Treat Diseases
On A Mission to Improve the Standard of Care For Difficult to Treat Diseases 100 Thyroid Testis Prostate Melanoma HR+ HER2- BC CLL HR+ HER2+ BC HL 5-Year Survival, 2012-2108 (%) HR- HER2+ BC Endometrial 80 Bladder CML TNBC RCC ALL Anal NHL Vulva Small Intestine Cervical Oral Cavity & Pharynx Bone Sa
Slide 17: Long-term Expansion of R&D Strategy Beyond "5x5"
Long-term Expansion of R&D Strategy Beyond "5x5" R&D Strategy • Focus on developing new product candidates with the potential for two new IND's annually from 2027+ • Seek to expand therapeutic focus into autoimmune and inflammatory disease • Seek to expand research interests into multifunctional eng
Slide 18: AD-VAN-CE Beyond 5 x 5
AD-VAN-CE Beyond 5 x 5 • Advancing design of ADCs and Multi-specifics to address complex disease states • Continue to apply technology to hard-to-treat cancers and expand utility to additional therapeutic applications ADCs Multi-specific Cell Engagers • Bispecific/Biparatopic(s) • Next Gen T Cell En
Slide 19: Milestone Opportunities in 2024 & 2025
Milestone Opportunities in 2024 & 2025 Several opportunities for business Cash resources as of September development with global rights for 30, 2023 $390.2M* novel compounds Current cash runway anticipated to Multiple value generating support development goals through opportunities expected in 2024
Slide 20: Q&A
Q&A Kenneth Galbraith Chair and CEO Chris Astle, Ph.D. SVP and CFO Paul Moore, Ph.D. CSO Making a Meaningful Difference 20
Slide 21: Q3 2023 Financial Results – Reconciliation of Non-GAAP Measures
Q3 2023 Financial Results – Reconciliation of Non-GAAP Measures Nine months ended Nine months ended Nine months ended Nine months ended In millions USD In millions USD Sept 30, 2023 Sept 30, 2022 Sept 30, 2023 Sept 30, 2022 R&D expenses $118.1 $155.6 G&A expenses $55.6 $43.2 Stock-based compensation
Slide 22: Differentiated Development of Multi-Specific Antibody Therapeutics
Differentiated Development of Multi-Specific Antibody Therapeutics Versatile multi-specific antibody therapeutics optimizing potency and precision with proven track record and robust clinical pipeline Program Potential Indication Target(s) Preclinical Phase 1 Phase 2 Pivotal Collaboration Partners Z
Slide 23: Differentiated Development of Antibody Drug Conjugates
Differentiated Development of Antibody Drug Conjugates Designing next-generation antibody drug conjugates (ADCs) on targets with evidence of clinical activity and addressing areas of unmet therapeutic potential Program Potential Target(s) Payload DAR (Range) Preclinical Phase 1 Phase 2 Pivotal Colla